Literature DB >> 25253573

Current and investigational drugs for the prevention of migraine in adults and children.

Frederick G Freitag1, Derrick Shumate.   

Abstract

There are only a handful of drugs that have been submitted for and received an indication for the preventative treatment of migraine by the US Food and Drug Administration, as well as international governmental regulatory agencies. However, there are a wide variety of agents that are used for this indication with different levels of evidence for efficacy and tolerability. Several guidelines have been published in recent years examining the evidence-based medicine of migraine preventative therapy and these provide guidance especially for the primary care clinician, but also for neurologists whose primary focus is not headache medicine. Some of the therapies are used in children and adolescents while others are used more commonly in adults. In the adult population, an evolutive state of migraine is more commonly seen than in young persons, that is chronic migraine. There is a paucity of evidence for medications for this stage of migraine but there is a single agent that is approved for this use but not for use in the treatment of episodic migraine. There have been few advances in the field of migraine-preventative medications in recent years but potential novel approaches are in development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253573     DOI: 10.1007/s40263-014-0202-2

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  38 in total

1.  Safety of a patented special butterbur root extract for migraine prevention.

Authors:  Ulrich Danesch; Reiner Rittinghausen
Journal:  Headache       Date:  2003-01       Impact factor: 5.887

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.

Authors:  Marcelo E Bigal; Rafael Escandon; Michele Bronson; Sarah Walter; Maria Sudworth; John P Huggins; Pamela Garzone
Journal:  Cephalalgia       Date:  2013-12-23       Impact factor: 6.292

5.  Propranolol for migraine prophylaxis.

Authors:  B Forssman; K G Henriksson; V Johannsson; L Lindvall; H Lundin
Journal:  Headache       Date:  1976-11       Impact factor: 5.887

6.  Botox treatment for migraine and chronic daily headache in adolescents.

Authors:  Valerie W Chan; E Jane McCabe; Daune L MacGregor
Journal:  J Neurosci Nurs       Date:  2009-10       Impact factor: 1.230

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

9.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

10.  Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial.

Authors:  Seyed Ali Sonbolestan; Kiyan Heshmat; Shaghayegh Haghjooy Javanmard; Mohammad Saadatnia
Journal:  Int J Prev Med       Date:  2013-01
View more
  2 in total

Review 1.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 2.  Recent advances in migraine therapy.

Authors:  Fabio Antonaci; Natascia Ghiotto; Shizheng Wu; Ennio Pucci; Alfredo Costa
Journal:  Springerplus       Date:  2016-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.